Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.196
+0.006 (+0.50%)
Streaming Delayed Price
Updated: 10:54 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atai Life Sciences N.V.
< Previous
1
2
...
17
18
19
20
21
22
23
24
Next >
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
January 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments
January 27, 2022
ATAI Life Sciences (NASDAQ: ATAI) on Tuesday announced Invyxis, a new program to accelerate the company’s portfolio of compounds.
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:
Via
Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
January 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...
Via
Benzinga
Why Jim Cramer Likes Illumina And Enterprise Products Partners
January 06, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ:
Via
Benzinga
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
January 02, 2022
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the...
Via
Talk Markets
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
December 30, 2021
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...
Via
Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
Mobile Clinics Featuring Novel Mental Health Treatments Reportedly Coming to Florida and Nevada
December 20, 2021
Photo by Insung Yoon on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
46 Biggest Movers From Yesterday
December 16, 2021
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
December 15, 2021
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...
Via
Benzinga
Dow Down Triple Digits as Fed Meeting Wraps Up
December 15, 2021
Stocks have deepened their morning losses by midday, with the Dow Jones Industrial Average down 119 points, while both the Nasdaq Composite and S&P 500 Index are firmly in the red as well.
Via
Talk Markets
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates
December 15, 2021
Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S...
Via
Benzinga
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
December 13, 2021
Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
December 13, 2021
Photo by Raimond Klavins
Via
Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics...
Via
Benzinga
Topics
Death
Exposures
Death
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
December 08, 2021
Photo by Michael Longmire on...
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.